Treatment of depression in HIV positive individuals: A critical review

References

• Acuff C, Archambeault J, Greenberg B, et al. Mental health care for people living with or affected by HIV/AIDS: A practical guide. Research Triangle Institute, Research Triangle Park, NC 1999
   Google Scholar
• Avants SK, Margolin A, Warburton LA, Hawkins KA, Shi J. Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. American Journal on Addictions 2001; 10: 69–78
   PubMed Web of Science ®Google Scholar
• Bing E, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Archives of General Psychiatry 2001; 58: 721–728
   PubMed Web of Science ®Google Scholar
• Carrico AW, Antoni MH, Duran RE, Ironson G, Penedo F, Fletcher MA, et al. Reductions in depressed mood and denial coping during cognitive behavioral stress management with HIV-positive gay men treated with HAART. Annals of Behavioral Medicine 2006; 31: 155–164
   PubMed Web of Science ®Google Scholar
• Charney DS, Nemeroff CB, Lewis L, Laden SK, Gorman JM, Laska EM, et al. National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Archives of General Psychiatry 2002; 59: 262–270
   PubMedGoogle Scholar
• Cruess DG, Douglas SD, Petitto JM, Leserman J, Have TT, Gettes D, et al. Association of depression, CD8+ T lymphocytes, and natural killer cell activity: Implications for morbidity and mortality in human immunodeficiency virus disease. Current Psychiatry Reports 2003; 5: 445–450
   PubMedGoogle Scholar
• Currier MB, Molina G, Kato M. Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: A prospective study. Psychosomatics 2004; 45: 210–216
   PubMed Web of Science ®Google Scholar
• Elliot AJ, Uldall KK, Bergam K, Russo J, Claypoole K, Roy-Byrne PP. Randomized placebo-controlled trial of paroxetine versus imipramine in depressed HIV+ outpatients. American Journal of Psychiatry 1998; 155: 367–372
   PubMedGoogle Scholar
• Elliot AJ, Roy-Byrne PP. Mirtazapine for depression in patients with human immunodeficiency virus. Journal of Clinical Psychopharmacology 2000; 20: 265–267
   PubMedGoogle Scholar
• Farber EW, McDaniel JS. Clinical management of psychiatric disorders in patients with HIV disease. Psychiatric Quarterly 2002; 73: 5–16
   PubMedGoogle Scholar
• Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. General Hospital Psychiatry 1997; 19: 89–97
   PubMed Web of Science ®Google Scholar
• Ferrando SJ, Rabkin JG, de Moore GM, Rabkin R. Antidepressant treatment of depression in HIV-seropositive women. Journal of Clinical Psychiatry 1999; 60: 741–746
   PubMed Web of Science ®Google Scholar
• Gillenwater DR, McDaniel JS. Rational psychopharmacology for patients with HIV infection and AIDS. Psychiatric Annals 2001; 31: 28–34
   Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, Shadler RI. Drug interactions with newer antidepressants: Role of human cytochromes P450. Journal of Clinical Psychiatry 1998; 59(Suppl.15)19–27
   PubMed Web of Science ®Google Scholar
• Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clinical Therapeutics 2003; 25: 1200–1210
   PubMed Web of Science ®Google Scholar
• Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: Longitudinal analysis from the HIV epidemiology research study. Journal of the American Medical Association 2001; 285: 1466–1474
   PubMed Web of Science ®Google Scholar
• Laperriere A, Ironson GH, Antoni MH, Pomm H, Jones D, Ishii M, et al. Decreased depression up to one year following CBSM+ intervention in depressed women with AIDS: The smart/EST women's project. Journal of Health Psychology 2005; 10: 223–231
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Hoover DR, Guccione M, Dew MA, Wesch JE, Bing EG, et al. Changes in depressive symptoms as AIDS develops. American Journal of Psychiatry 1996; 153: 1430–1437
   PubMed Web of Science ®Google Scholar
• Manning D, Jacobsberg L, Erhart S. The efficacy of imipramine in the treatment of HIV-related depression. Presented at the 7th International Conference on AIDS, San Francisco, June 16–20, 1990, CA, Abstract ThB32
   Google Scholar
• Markowitz JC, Kocsis JH, Fishman B, Spielman LA, Jacobsberg LB, Frances AJ, et al. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Archives of General Psychiatry 1998; 55: 452–457
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry 1996; 153: 311–320
   PubMed Web of Science ®Google Scholar
• Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV Outpatient Study. Journal of Acquired Immune Deficiency Syndromes 2006; 43: 27–34
   PubMed Web of Science ®Google Scholar
• Penzak SR, Reddy YS, Grimsley SR. Depression in patients with HIV infection. American Journal of Health-System Pharmacy 2000; 57: 376–386
   PubMed Web of Science ®Google Scholar
• Poretsky L, Brillon DJ, Ferrando S, Chiu J, McElhiney M, Ferenczi A, et al. Endocrine effects of oral dehydroepiandrosterone in men with HIV infection: A prospective, randomized, double-blind, placebo-controlled trial. Metabolism 2006; 55: 858–870
   PubMedGoogle Scholar
• Rabkin JG, Rabkin R, Harrison W, Wagner G. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. American Journal of Psychiatry 1994a; 151: 516–523
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Rabkin R, Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. Journal of Clinical Psychiatry 1994b; 55: 92–97
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Wagner G, Rabkin R. Effects of sertraline on mood and immune status in patients with major depression and HIV illness: An open trial. Journal of Clinical Psychiatry 1994c; 55: 433–439
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Ferrando SJ, Jacobsberg LB, Fishman B. Prevalence of axis I disorders in an AIDS cohort: A cross-sectional, controlled study. Comprehensive Psychiatry 1997; 38: 146–154
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: A randomized, placebo-controlled trial. American Journal of Psychiatry 1999a; 156: 101–107
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Wagner G, Rabkin R. Testosterone therapy for HIV+ men with and without hypogonadism. Journal of Clinical Psychopharmacology 1999b; 19: 19–27
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Ferrando SJ, Lin SH, Sewell M, McElhiney M. Psychological effects of HAART: A 2-year study. Psychosomatic Medicine 2000a; 62: 413–422
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Archives of General Psychiatry 2000b; 57: 141–147
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Sun HL. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: A placebo controlled trial. Journal of Clinical Psychopharmacology 2004a; 24: 379–385
   PubMed Web of Science ®Google Scholar
• Rabkin JG, McElhiney MC, Rabkin R, Ferrando SJ. Modafinil treatment for fatigue in HIV+ patients: A pilot study. Journal of Clinical Psychiatry 2004b; 65: 1688–1695
   PubMedGoogle Scholar
• Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. American Journal of Psychiatry 2006; 163: 59–66
   PubMed Web of Science ®Google Scholar
• Schwartz JAJ, McDaniel JS. Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: A pilot study. Depression and Anxiety 1999; 9: 70–74
   PubMedGoogle Scholar
• Starace S, Ammassari A, Trotta MP, De Longis P, Izzo C, Scalzini A, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2002; 31(Suppl.3)136–139
   PubMed Web of Science ®Google Scholar
• Targ EF, Karasic DH, Diefenbach PN, Anderson PA, Bystrisky A, Fawzi FI. Structured group therapy and fluoxetine to treat depression in HIV-positive persons. Psychosomatics 1994; 35: 132–137
   PubMed Web of Science ®Google Scholar
• Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. American Journal of Medicine 2003; 114: 573–580
   PubMed Web of Science ®Google Scholar
• Wagner GJ, Maguen S, Rabkin JG. Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatric Services 1998; 49: 239–240
   PubMed Web of Science ®Google Scholar
• Yun LWH, Maravi M, Koayashi JS, Barton PL, Davidson AJ. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2005; 38: 432–438
   PubMed Web of Science ®Google Scholar
• Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I. Treatment of major depression in HIV-seropositive men. Journal of Clinical Psychiatry 1998; 59: 217–224
   PubMed Web of Science ®Google Scholar